Recruiting

Xiidra

Sponsor:

UCLA

Code:

NCT04354545

Conditions

Glaucoma

Ocular Surface Disease

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Accepted

Interventions

Xiidra (Lifitegrast ophthalmic solution) 5%

Study Details

Brief summary:

To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.

Conditions

Glaucoma

Ocular Surface Disease

Study ID

NCT04354545

Start date

Apr 1, 2021

Status verified date

Dec, 2025

Completion date

Dec 1, 2026

Anticipated

Primary completion date

Dec 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Currently using one or more topical glaucoma antihypertensives
  • Self-described symptoms of ocular surface discomfort
  • Xiidra is being prescribed as part of the subject's standard care

Exclusion Criteria:

  • History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.),
  • current use of topical cyclosporine
  • current use of topical steroids
  • incisional ocular surgery within 6 months

Study Design

Enrollment

75 participants

Anticipated

Interventions and Outcome Measures

Arms

Group 1

Xiidra (Lifitegrast ophthalmic solution) 5% applied to both eye (OU) for 12 weeks

Interventions

Xiidra (Lifitegrast ophthalmic solution) 5%

FDA approved lifitegrast opthalmic solution eye drop

Primary outcome measure

  • Change from baseline to week 12 in corneal fluorescein staining score [ Time Frame: From baseline to Week 12 ]
  • Change from baseline to week 12 in eye dryness score (EDS) [ Time Frame: From baseline to Week 12 ]
  • Change from baseline to week 12 in ocular surface disease index (OSDI) questionnaire score [ Time Frame: From baseline to Week 12 ]

Central Contacts and Locations

Central contacts

Benjamin B Bert, MD

626-817-4701BBert@mednet.ucla.edu

Mayra Raygoza

16268174747Mraygoza@mednet.ucla.edu

Locations

Doheny Eye Center UCLA

Recruiting

Fountain Valley, California, United States, 92708

Contacts

Benjamin B Bert, MD

7149631444JanettMendez@mednet.ucla.edu

More Information

Sponsor

University of California, Los Angeles

Last update posted

Mar 13, 2026

Last verified

Dec, 2025

Keywords

  • glaucoma
  • xiidra™
  • ocular surface discomfort

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, Los Angeles on 2026-03-13.